Bone health in diabetes: Considerations for clinical management

Current Medical Research and Opinion

Volumn 25, Issue 5, 2009, Pages 1057-1072

  Adami, Silvano ^a,b  

^a UNIVERSITY OF VERONA   (Italy)

^b Ospedale di Valeggio   (Italy)

Author keywords

Antihyperglycaemics; Bone; Diabetes; Fracture; Thiazolidinediones

Indexed keywords

ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; CARBOXY TERMINAL TELOPEPTIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; METFORMIN; OSTEOCALCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; TROGLITAZONE;

BONE DENSITY; BONE MASS; CORRELATION ANALYSIS; DIABETES MELLITUS; DRUG INDICATION; FALLING; FEMUR NECK; FOOT FRACTURE; HIP FRACTURE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOPOROSIS; PATHOPHYSIOLOGY; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SIDE EFFECT;

ANIMALS; BONE AND BONES; BONE DENSITY; DIABETES COMPLICATIONS; DIABETES MELLITUS; FRACTURES, BONE; HEALTH; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, BIOLOGICAL; RISK FACTORS;

EID: 67649398909     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902801147     Document Type: Review

References (145)

1. Morrison LB, Bogan IK. Bone development in diabetic children: a roentgen study. Am J Med Sci 1927;174:313-318
2. Schwartz AV, Sellmeyer DE. Diabetes, fracture, and bone fragility. Curr Osteoporos Rep 2007;5:105-111
3. Bagger YZ, Tanko LB, Alexandersen P, et al. The long-term predictive value of bone mineral density measurements for fracture risk is independent of the site of measurement and the age at diagnosis: results from the Prospective Epidemiological Risk Factors study. Osteoporos Int 2006;17:471-477
4. Friedman AW. Important determinants of bone strength: beyond bone mineral density. J Clin Rheumatol 2006;12:70-77 (Pubitemid 44309600)
5. Lu H, Kraut D, Gerstenfeld LC, et al. Diabetes interferes with the bone formation by affecting the expression of transcription factors that regulate osteoblast differentiation. Endocrinology 2003;144:346-352 (Pubitemid 36076124)
6. Thrailkill KM, Liu L, Wahl EC, et al. Bone formation is impaired in a model of type 1 diabetes. Diabetes 2005; 54:2875-2881 (Pubitemid 41401082)
7. Alexopoulou O, Jamart J, Devogelaer JP, et al. Bone density and markers of bone remodeling in type 1 male diabetic patients. Diabetes Metab 2006;32:453-458 (Pubitemid 44836587)
8. Bjorgaas M, Haug E, Johnsen HJ. The urinary excretion of deoxypyridinium cross-links is higher in diabetic than in nondiabetic adolescents. Calcif Tissue Int 1999;65:121-124 (Pubitemid 29350648)
9. Karaguzel G, Akcurin S, Ozdem S, et al. Bone mineral density and alterations of bone metabolism in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2006;19:805-814 (Pubitemid 44083537)
10. Krakauer JC, McKenna MJ, Buderer NF, et al. Bone loss and bone turnover in diabetes. Diabetes 1995;44:775-782
11. Mathiassen B, Nielsen S, Johansen JS, et al. Long-term bone loss in insulin-dependent patients with microvascular complications. J Diabetes Complicat 1990;4:145-149
12. Munoz-Torres M, Jodar E, Escobar-Jimenez F, et al. Bone mineral density measured by dual X-ray absorptiometry in Spanish patients with insulin-dependent diabetes mellitus. Calcif Tissue Int 1996;58:316-319 (Pubitemid 26136794)
13. Olmos JM, Perez-Castrillon JL, Garcia MT, et al. Bone densitometry and biochemical bone remodeling markers in type 1 diabetes mellitus. Bone Miner 1994;26:1-8 (Pubitemid 2115335)
14. Lopez-Ibarra PJ, Pastor MM, Escobar-Jimenez F, et al. Bone mineral density at time of clinical diagnosis of adult-onset type 1 diabetes mellitus. Endocr Pract 2001;7:346-351 (Pubitemid 32904291)
15. Hui SL, Epstein S, Johnston Jr CC. A prospective study of bone mass in patients with type 1 diabetes. J Clin Endocrinol Metab 1985;60:74-80 (Pubitemid 15194651)
16. Bouillon R. Diabetic bone disease. Calcif Tissue Int 1991; 49:155-160
17. Forst T, Pfutzner A, Kann P, et al. Peripheral osteopenia in adult patients with insulin-dependent diabetes mellitus. Diabet Med 1995;12:874-879
18. Miazgowski T, Czekalski S. A 2-year follow-up study on bone mineral density and markers of bone turnover in patients with long-standing insulin-dependent diabetes mellitus. Osteoporos Int 1998;8:399-403 (Pubitemid 28486705)
19. Piepkorn B, Kann P, Forst T, et al. Bone mineral density and bone metabolism in diabetes mellitus. Horm Metab Res 1997;29:584-591 (Pubitemid 28053672)
20. Tuominen JT, Impivaara O, Puukka P, et al. Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care 1999;22:1196-1200 (Pubitemid 29293977)
21. McNair P, Christiansen C, Christensen MS, et al. Development of bone mineral loss in insulin-treated diabetes: a 1 1/2 years follow-up study in sixty patients. Eur J Clin Invest 1981;11:55-59
22. Mastrandrea LD, Wactawski-Wende J, Donahue RP, et al. Young women with type 1 diabetes have lower bone mineral density that persists over time. Diabetes Care 2008; 31:1729-1735
23. Forsen L, Meyer HE, Midthjell K, et al. Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trøndelag Health Survey. Diabetologia 1999;42:920-925 (Pubitemid 29369598)
24. Janghorbani M, Hu FB, Willett WC, et al. Prospective study of type 1 and 2 diabetes and risk of stroke subtypes: The Nurse's Health Study. Diabetes Care 2007;30:1730-1735 (Pubitemid 47036344)
25. Miao J, Brismar K, Nyren O, et al. Elevated hip fracture risk in type 1 diabetic patients: a population-based cohort study in Sweden. Diabetes Care 2005;28:2850-2855 (Pubitemid 43942914)
26. Nicodemus KK, Folsom AR. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 2001;24:1192-1197 (Pubitemid 33716397)
27. Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 2005;48:1292-1299 (Pubitemid 41186093)
28. Heath III H, Melton III LJ, Chu CP. Diabetes mellitus and risk of skeletal fracture. N Engl J Med 1980;303:567-570 (Pubitemid 10046835)
29. Melchior TM, Sorensen H, Torp-Pedersen C. Hip and distal arm fracture rates in peri- and postmenopausal insulin-treated diabetic females. J Intern Med 1994;236:203-208 (Pubitemid 24246978)
30. Janghorbani M, Van Dam RM, Willett WC, et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007;166:495-505 (Pubitemid 47283633)
31. Ahmed LA, Joakimsen RM, Berntsen GK, et al. Diabetes mellitus and the risk of non-vertebral fractures: the Tromso study. Osteoporos Int 2006;17:495-500
32. Kelsey JL, Browner WS, Seeley DG, et al. Risk factors for fractures of the distal forearm and proximal humerus. The Study of Osteoporotic Fractures Research Group. Am J Epidemiol 1992;135:477-489
33. Achemlal L, Tellal S, Rkiouak F, et al. Bone metabolism in male patients with type 2 diabetes. Clin Rheumatol 2005; 24:493-496 (Pubitemid 43055041)
34. Pietschmann P, Schernthaner G, Woloszczuk W. Serum osteocalcin levels in diabetes mellitus: analysis of the type of diabetes and microvascular complications. Diabetologia 1988; 31:892-895 (Pubitemid 19054759)
35. Dobnig H, Piswanger-Sölkner JC, Roth M, et al. Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk. J Clin Endocrinol Metab 2006; 91:3355-3363 (Pubitemid 44402104)
36. Knudsen ST, Foss CH, Poulsen PL, et al. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 2003; 149:39-42 (Pubitemid 36874202)
37. De Leeuw I, Abs R. Bone mass and bone density in maturitytype diabetics measured by the 125I photon-absorption technique. Diabetes 1977;26:1130-1135 (Pubitemid 8283433)
38. Levin ME, Boisseau VC, Avioli LV. Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes. N Engl J Med 1976;294:241-245
39. de Liefde II, van der KM, de Laet CE, et al. Bone mineral density and fracture risk in type 2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 2005;16:1713-1720 (Pubitemid 41790880)
40. Ivers RQ, Cumming RG, Mitchell P, et al. Diabetes and risk of fracture: The Blue Mountains Eye Study. Diabetes Care 2001;24:1198-1203 (Pubitemid 33716398)
41. Lunt M, Masaryk P, Scheidt-Nave C, et al. The effects of lifestyle, dietary dairy intake and diabetes on bone density and vertebral deformity prevalence: the EVOS study. Osteoporos Int 2001;12:688-698 (Pubitemid 32889170)
42. Schwartz AV, Sellmeyer DE, Ensrud KE, et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 2001;86:32-38 (Pubitemid 32109771)
43. van Daele PL, Stolk RP, Burger H, et al. Bone density in non-insulin- dependent diabetes mellitus. The Rotterdam Study. Ann Intern Med 1995;122:409-414
44. Wakasugi M, Wakao R, Tawata M, et al. Bone mineral density measured by dual energy x-ray absorptiometry in patients with non-insulin-dependent diabetes mellitus. Bone 1993; 14:29-33 (Pubitemid 23081246)
45. Barrett-Connor E, Holbrook TL. Sex differences in osteoporosis in older adults with non-insulin-dependent diabetes mellitus. J Am Med Assoc 1992;268:3333-3337
46. Isaia GC, Ardissone P, Di Stefano M, et al. Bone metabolism in type 2 diabetes mellitus. Acta Diabetol 1999;36:35-38
47. Sosa M, Dominguez M, Navarro MC, et al. Bone mineral metabolism is normal in non-insulin-dependent diabetes mellitus. J Diabetes Complicat 1996;10:201-205 (Pubitemid 26270743)
48. Broussard DL, Magnus JH. Influence of cardiovascular disease risk factors on the relationship between low bone mineral density and type 2 diabetes mellitus in a multiethnic US population of women and men: a cross-sectional study. Gend Med 2008;5:229-238
49. Hosoda H, Fukui M, Nakayama I, et al. Bone mass and bone resorption in postmenopausal women with type 2 diabetes mellitus. Metabolism 2008;57:940-945 (Pubitemid 351814686)
50. Bauer DC, Browner WS, Cauley JA, et al. Factors associated with appendicular bone mass in older women. The Study of Osteoporotic Fractures Research Group. Ann Intern Med 1993;118:657-665 (Pubitemid 23118035)
51. Dennison EM, Syddall HE, Aihie SA, et al. Type 2 diabetes mellitus is associated with increased axial bone density in men and women from the Hertfordshire Cohort Study: evidence for an indirect effect of insulin resistance? Diabetologia 2004; 47:1963-1968
52. Gerdhem P, Isaksson A, Akesson K, et al. Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Osteoporos Int 2005;16:1506-1512 (Pubitemid 41790853)
53. Schwartz AV, Sellmeyer DE, Strotmeyer ES, et al. Diabetes and bone loss at the hip in older black and white adults. J Bone Miner Res 2005;20:596-603 (Pubitemid 40393067)
54. Barrett-Connor E, Kritz-Silverstein D. Does hyperinsulinemia preserve bone? Diabetes Care 1996;19:1388-1392
55. Ensrud KE, Thompson DE, Cauley JA, et al. Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group. J Am Geriatr Soc 2000;48:241-249
56. Hanley DA, Brown JP, Tenenhouse A, et al. Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: crosssectional results from the Canadian Multicentre Osteoporosis Study. J Bone Miner Res 2003;18:784-790 (Pubitemid 36899328)
57. Holmberg AH, Johnell O, Nilsson PM, et al. Risk factors for hip fractures in a middle-aged population: a study of 33,000 men and women. Osteoporos Int 2005;16:2185-2194 (Pubitemid 41790943)
58. Meyer HE, Tverdal A, Falch JA. Risk factors for hip fracture in middle-aged Norwegian women and men. Am J Epidemiol 1993;137:1203-1211 (Pubitemid 23205895)
59. Ottenbacher KJ, Ostir GV, Peek MK, et al. Diabetes mellitus as a risk factor for hip fracture in Mexican American older adults. J Gerontol A Biol Sci Med Sci 2002;57:M648-M653
60. Strotmeyer ES, Cauley JA, Schwartz AV, et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med 2005;165:1612-1617 (Pubitemid 41124155)
61. Lipscombe LL, Jamal SA, Booth GL, et al. The risk of hip fractures in older individuals with diabetes: a population-based study. Diabetes Care 2007;30:835-841 (Pubitemid 46556575)
62. Hans D, Durosier C, Kanis JA, et al. Assessment of the 10-year probability of osteoporotic hip fracture combining clinical risk factors and heel bone ultrasound: the EPISEM prospective cohort of 12,958 elderly women. J Bone Miner Res 2008; 23:1045-1051 (Pubitemid 351915726)
63. Melton III LJ, Leibson CL, Achenbach SJ, et al. Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res 2008;23:1334-1342 (Pubitemid 352040189)
64. Melton III LJ, Riggs BL, Leibson CL, et al. A bone structural basis for fracture risk in diabetes. J Clin Endocrinol Metab 2008;93:4804-4809
65. Rosato MT, Schneider SH, Shapses SA. Bone turnover and insulin- like growth factor I levels increase after improved glycemic control in noninsulin-dependent diabetes mellitus. Calcif Tissue Int 1998;63:107-111 (Pubitemid 28347682)
66. Botolin S, McCabe LR. Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. J Cell Biochem 2006;99:411-424 (Pubitemid 44435559)
67. Valerio G, del Puente A, Esposito-del Puente A, et al. The lumbar bone mineral density is affected by long-term poor metabolic control in adolescents with type 1 diabetes mellitus. Horm Res 2002;58:266-272 (Pubitemid 35404237)
68. Campos Pastor MM, Lopez-Ibarra PJ, Escobar-Jimenez F, et al. Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study. Osteoporos Int 2000;11:455-459 (Pubitemid 30450130)
69. Okazaki R, Totsuka Y, Hamano K, et al. Metabolic improvement of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover. J Clin Endocrinol Metab 1997; 82:2915-2920 (Pubitemid 27385648)
70. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis. Osteoporos Int 2007;18:427-444 (Pubitemid 46354916)
71. Jehle PM, Jehle DR, Mohan S, et al. Serum levels of insulin-like growth factor system components and relationship to bone metabolism in type 1 and type 2 diabetes mellitus patients. J Endocrinol 1998;159:297-306 (Pubitemid 28520183)
72. Raisz LG. Local and systemic factors in the pathogenesis of osteoporosis. N Engl J Med 1988;318:818-828 (Pubitemid 18083630)
73. Stolk RP, van Daele PL, Pols HA, et al. Hyperinsulinemia and bone mineral density in an elderly population: The Rotterdam Study. Bone 1996;18:545-549 (Pubitemid 26257875)
74. Haffner SM, Bauer RL. The association of obesity and glucose and insulin concentrations with bone density in premenopausal and postmenopausal women. Metabolism 1993; 42:735-738 (Pubitemid 23173413)
75. Kwon DJ, Kim JH, Chung KW, et al. Bone mineral density of the spine using dual energy X-ray absorptiometry in patients with non-insulin-dependent diabetes mellitus. J Obstet Gynecol Res 1996;22:157-162 (Pubitemid 126450151)
76. Falkner B, Sherif K, Sumner A, et al. Hyperinsulinism and sex hormones in young adult African Americans. Metabolism 1999;48:107-112 (Pubitemid 29035569)
77. Maturana MA, Spritzer PM. Association between hyperinsulinemia and endogenous androgen levels in peri- and postmenopausal women. Metabolism 2002;51:238-243 (Pubitemid 34168239)
78. Felson DT, Zhang Y, Hannan MT, et al. Effects of weight and body mass index on bone mineral density in men and women: the Framingham study. J Bone Miner Res 1993; 8:567-573 (Pubitemid 23127916)
79. Thomas T, Burguera B, Melton III LJ, et al. Role of serum leptin, insulin, and estrogen levels as potential mediators of the relationship between fat mass and bone mineral density in men versus women. Bone 2001;29:114-120 (Pubitemid 32734491)
80. Isaia GC, D'Amelio P, Di Bella S, et al. Is leptin the link between fat and bone mass? J Endocrinol Invest 2005; 28:61-65
81. Yamauchi M, Sugimoto T, Yamaguchi T, et al. Plasma leptin concentrations are associated with bone mineral density and the presence of vertebral fractures in postmenopausal women. Clin Endocrinol (Oxf) 2001;55:341-347 (Pubitemid 32823044)
82. Zoico E, Zamboni M, Adami S, et al. Relationship between leptin levels and bone mineral density in the elderly. Clin Endocrinol (Oxf) 2003;59:97-103 (Pubitemid 36774114)
83. Yokota T, Meka CS, Medina KL, et al. Paracrine regulation of fat cell formation in bone marrow cultures via adiponectin and prostaglandins. J Clin Invest 2002;109:1303-1310 (Pubitemid 34546894)
84. Einhorn TA, Boskey AL, Gundberg CM, et al. The mineral and mechanical properties of bone in chronic experimental diabetes. J Orthop Res 1988;6:317-323 (Pubitemid 18120498)
85. Reddy GK, Stehno-Bittel L, Hamade S, et al. The biomechanical integrity of bone in experimental diabetes. Diabetes Res Clin Pract 2001;54:1-8 (Pubitemid 32782639)
86. Verhaeghe J, Suiker AM, Einhorn TA, et al. Brittle bones in spontaneously diabetic female rats cannot be predicted by bone mineral measurements: studies in diabetic and ovariectomized rats. J Bone Miner Res 1994;9:1657-1667 (Pubitemid 24300118)
87. Fleischli JG, Laughlin TJ, Athanasiou K, et al. Effect of diabetes mellitus on the material properties of the distal tibia. J Am Podiatr Med Assoc 2006;96:91-95
88. Paul RG, Bailey AJ. Glycation of collagen: the basis of its central role in the late complications of ageing and diabetes. Int J Biochem Cell Biol 1996;28:1297-1310 (Pubitemid 27037919)
89. Ahmed N, Thornalley PJ. Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab 2007;9:233-245
90. Leidig-Bruckner G, Ziegler R. Diabetes mellitus a risk for osteoporosis? Exp Clin Endocrinol Diabetes 2001;109(Suppl 2):S493-S514
91. Wang X, Shen X, Li X, et al. Age-related changes in the collagen network and toughness of bone. Bone 2002;31:1-7 (Pubitemid 34754417)
92. McCarthy AD, Etcheverry SB, Cortizo AM. Advanced glycation endproduct-specific receptors in rat and mouse osteoblast-like cells: regulation with stages of differentiation. Acta Diabetol 1999;36:45-52
93. Kume S, Kato S, Yamagishi S, et al. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res 2005;20:1647-1658 (Pubitemid 41243553)
94. Katayama Y, Akatsu T, Yamamoto M, et al. Role of nonenzymatic glycosylation of type 1 collagen in diabetic osteopenia. J Bone Miner Res 1996;11:931-937 (Pubitemid 26200043)
95. McCarthy AD, Uemura T, Etcheverry SB, et al. Advanced glycation endproducts interefere with integrin-mediated osteoblastic attachment to a type 1 collagen matrix. Int J Biochem Cell Biol 2004;36:840-848 (Pubitemid 38299399)
96. Miyata T, Notoya K, Yoshida K, et al. Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol 1997;8:260-270 (Pubitemid 127455881)
97. Valcourt U, Merle B, Gineyts E, et al. Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentiation. J Biol Chem 2007;282:5691-5703 (Pubitemid 47093757)
98. Zhou Z, Immel D, Xi CX, et al. Regulation of osteoclast function and bone mass by RAGE. J Exp Med 2006; 203:1067-1080
99. Riis BJ, Hansen MA, Jensen AM, et al. Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study. Bone 1996; 19:9-12 (Pubitemid 26318738)
100. Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab 2006;91:3404-3410 (Pubitemid 44402111)
101. Nelson DA, Jacober SJ. Why do older women with diabetes have an increased fracture risk? J Clin Endocrinol Metab 2001;86:29-31
102. Wallace C, Reiber GE, LeMaster J, et al. Incidence of falls, risk factors for falls, and fall-related fractures in individuals with diabetes and a prior foot ulcer. Diabetes Care 2002; 25:1983-1986 (Pubitemid 41071055)
103. Schwartz AV, Hillier TA, Sellmeyer DE, et al. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care 2002;25:1749-1754 (Pubitemid 41071081)
104. Maurer MS, Burcham J, Cheng H. Diabetes mellitus is associated with an increased risk of falls in elderly residents of a long-term care facility. J Gerontol A Biol Sci Med Sci 2005;60:1157-1162 (Pubitemid 41384486)
105. Barrett-Connor E, Weiss TW, McHorney CA, et al. Predictors of falls among postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int 2008;Sept 19: [Epub ahead of Print]
106. Wei TS, Hu CH, Wang SH, et al. Fall characteristics, functional mobility and bone mineral density as risk factors of hip fracture in the community-dwelling ambulatory elderly. Osteoporos Int 2001;12:1050-1055 (Pubitemid 34105977)
107. Bellows CG, Jia D, Jia Y, et al. Different effects of insulin and insulin-like growth factors I and II on osteoprogenitors and adipocyte progenitors in fetal rat bone cell populations. Calcif Tissue Int 2006;79:57-65 (Pubitemid 44198293)
108. Gandhi A, Beam HA, O'Connor JP, et al. The effects of local insulin delivery on diabetic fracture healing. Bone 2005; 37:482-490 (Pubitemid 41317321)
109. Monami M, Cresci B, Colombini A, et al. Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. Diabetes Care 2008;31:199-203 (Pubitemid 351213319)
110. Cortizo AM, Sedlinsky C, McCarthy AD, et al. Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture. Eur J Pharmacol 2006;536:38-46
111. Schurman L, McCarthy AD, Sedlinsky C, et al. Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells. Exp Clin Endocrinol Diabetes 2008;116:333-340 (Pubitemid 351947863)
112. Kahn SE, Haffner S, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443 (Pubitemid 44903747)
113. Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008;31:845-851
114. Home PD, Jones NP, Pocock SJ, et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med 2007;24:626-634 (Pubitemid 46808876)
115. Dormandy JA, Charbonnel B, Eckland D, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366: 1279-1289 (Pubitemid 41416583)
116. Takeda. Dear Healthcare Provider Letter. Observation of an increased incidence of fractures in female patients who received long-term treatments with Actos® (pioglitazone HCl) tablets for type 2 diabetes mellitus. Available from http://www.fda.gov/medwatch/safety/2007/Actosmar0807. pdf [Last accessed 1 Dec 2008]
117. Meymeh RH, Wooltorton E. Diabetes drug pioglitazone (Actos): risk of fracture. CMAJ 2007;177:723-724
118. Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008; 168:820-825 (Pubitemid 351620084)
119. GlaxoSmithKline. Dear Healthcare Provider Letter, re: clinical trial observation of an increased incidence of fractures in female patients who received long-term treatment with Avandia® (rosiglitazone maleate) tablets for type 2 diabetes mellitus. Available from http://www.fda.gov/MedWatch/safety/ 2007/Avandia-GSK-Ltr.pdf [Last accessed 4 Dec 2008]
120. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006;91:3349-3354 (Pubitemid 44402103)
121. Berberoglu Z, Gursoy A, Bayraktar N, et al. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 2007;92:3523-3530 (Pubitemid 47435330)
122. Grey A, Bolland M, Gamble G, et al. The peroxisome-proliferator- activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007;92:1305-1310 (Pubitemid 46556402)
123. Yaturu S, Bryant B, Jain SK. Thiazolidinediones treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care. In press.
124. Rubin GL, Zhao Y, Kalus AM, et al. Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res 2000;60:1604-1608 (Pubitemid 30183431)
125. Seto-Young D, Paliou M, Schlosser J, et al. Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. J Clin Endocrinol Metab 2005;90:6099-6105 (Pubitemid 41606531)
126. Azziz R, Ehrmann DA, Legro RS, et al. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril 2003;79:932-937 (Pubitemid 36385016)
127. Weitzmann MN, Pacifici R. Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 2006;116:1186-1194
128. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev 2002;18(Suppl 2):S10-S15 (Pubitemid 34467309)
129. Pei L, Tontonoz P. Fat's loss is bone's gain. J Clin Invest 2004;113:805-806 (Pubitemid 38544136)
130. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;418:41-49 (Pubitemid 34742565)
131. Wan Y, Chong LW, Evans RM. PPAR-gamma regulates osteoclastogenesis in mice. Nat Med 2007;13:1496-1503
132. Benvenuti S, Cellai I, Luciani P, et al. Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells. J Endocrinol Invest 2007;30:RC26- RC30 (Pubitemid 350238195)
133. Gimble JM, Robinson CE, Wu X, et al. Peroxisome proliferator- activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol 1996;50:1087-1094 (Pubitemid 26384846)
134. Lazarenko OP, Rzonca SO, Suva LJ, et al. Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone 2006;38:74-84 (Pubitemid 43006077)
135. Lecka-Czernik B, Gubrij I, Moerman EJ, et al. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Cell Biochem 1999;74:357-371 (Pubitemid 29344887)
136. Ali AA, Weinstein RS, Stewart SA, et al. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005;146:1226-1235 (Pubitemid 40289310)
137. Lazarenko OP, Rzonca SO, Hogue WR, et al. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 2007;148:2669-2680 (Pubitemid 46984815)
138. Rzonca SO, Suva LJ, Gaddy D, et al. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004; 145:401-406 (Pubitemid 38094536)
139. Sottile V, Seuwen K, Kneissel M. Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif Tissue Int 2004;75:329-337 (Pubitemid 40064235)
140. Tornvig L, Mosekilde LI, Justesen J, et al. Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice. Calcif Tissue Int 2001;69:46-50 (Pubitemid 32702265)
141. Akune T, Ohba S, Kamekura S, et al. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004;113:846-855 (Pubitemid 38544143)
142. Soroceanu MA, Miao D, Bai XY, et al. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 2004;183:203-216 (Pubitemid 40124657)
143. Lecka-Czernik B, Ackert-Bicknell C, Adamo ML, et al. Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the IGF regulatory system in vitro and in vivo. Endocrinology 2007;148:903-911 (Pubitemid 46143190)
144. Adami S, Kanis JA. Assessment of involutional bone loss: methodological and conceptual problems. J Bone Miner Res 1995;10:511-517
145. Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008;168:820-825 (Pubitemid 351620084)